Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK1070806 + dupilumab
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
**GSK1070806 + dupilumab** is a combination of two monoclonal antibodies used in clinical research for the treatment of moderate to severe atopic dermatitis, particularly in patients who have not responded adequately to prior therapies. GSK1070806 is a humanized IgG1 monoclonal antibody targeting and neutralizing interleukin-18 (IL-18), an important cytokine in the inflammatory pathway, thereby inhibiting IL-18–induced IFN-γ production. Dupilumab is a monoclonal antibody that blocks the shared receptor component for interleukin-4 (IL-4) and interleukin-13 (IL-13), thereby inhibiting signaling of these cytokines involved in type 2 inflammation. The combination is being explored primarily for potential benefit in atopic dermatitis, with GSK1070806 specifically under trial in patients inadequately responsive to dupilumab therapy.
- Brand names
- Dupixent
- Other names
- GSK1070806 + Dupixent
02
Targets
IL4R (Interleukin-4 receptor alpha subunit)IL18 (Interleukin-18)
Beyond the preview
Go deeper on GSK1070806 + dupilumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK1070806 + dupilumab.